Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[Buddhahead]

The Inflammation Link: NF-?B Remains a Difficult but Intriguing Target in OncLive, Jane de Lartigue, PhD, Published Online: Friday, June 28, 2013

Excerpt:
"While anticancer therapies aimed at particular pathways have mushroomed in recent years, one crucial target has remained elusive: nuclear factor kappa-light-chain-enhancer of activated B cells (NF-?B). The pathway is constitutively active in the majority of cancers and provides a mechanistic link between chronic inflammation and tumorigenesis. As such, it represents an important target for anticancer therapy. The complex regulation of NF-?B activation has presented significant challenges for the development of such agents, but researchers are now beginning to better understand and embrace this complexity to drive development of a variety of novel NF-?B-targeting strategies."

Article at:
http://www.onclive.com/publications/oncology-live/2013/june-2013/the-inflammation-link-nf-b-remains-a-difficult-but-intriguing-target/1#sthash.vBupZeXI.dpuf